Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medical Innovation

Rutgers New Jersey Medical School Scientists Study How Worm Infections Can Weaken Immune Systems — And Life-Saving Vaccinations

New Brunswick, NJ, August 9, 2017 — Why are malaria, tuberculosis and hepatitis so prevalent in developing nations?  And why are most vaccines against these pathogens so ineffective?

Two Rutgers New Jersey Medical School scientists believe they may have found an answer in parasitic intestinal worms — which infect more than 1.5 billion people worldwide and can weaken the immune system’s ability to fend off disease, rendering vaccines less effective.

George Yap and William Gause received a $3 million grant from the National Institutes of Health this spring to study how worms prevent vaccinations from bolstering the immune system. Continue reading

Medical Innovation: First Human Embryo Editing Experiment in U.S. ‘Corrects’ Gene for Heart Condition

New York, NY, August 3, 2017 — Ariana Eunjung Cha reports in The Washington Post that scientists have successfully edited the DNA of human embryos to erase a heritable heart condition that is known for causing sudden death in young competitive athletes, cracking open the doors to a controversial new era in medicine.

This is the first time gene editing on human embryos has been conducted in the United States. Researchers said in interviews this week that they consider their work very basic.

The embryos were allowed to grow for only a few days, and there was never any intention to implant them to create a pregnancy. Continue reading

Commercial Center for Innovative Technologies Adds Genomic Prediction, A Startup Fertility Treatment Company

North Brunswick, NJ, August 3, 2017 — Vince Calio reports in NJBIZ that the Commercial Center for Innovative Technologies has a new addition to its family, as Genomic Prediction, a startup fertility treatment company, has moved into the space — and is growing already.

The company was co-founded by Rutgers University associate professor Nathan Treff, and specializes in testing human embryos for a range of chromosomal abnormalities and genetic disorders before they are implanted in women who are seeking in vitro fertilization to become pregnant.

So far, the company’s long-term focus is on developing polygenic tests to predict the risk of diabetes and other conditions. Continue reading

Choose New Jersey CEO Michele Brown: ‘Access to Lab Space, Funding and Partners Help Biotech Companies Grow in Garden State’

Michele Brown (Photo: NJBIZ/Aaron Houston)

Trenton, NJ, August 1, 2017Choose New Jersey, Inc. led a delegation representing more than 20 New Jersey organizations — including top life sciences companies, universities, trade associations, state officials — as it showcased New Jersey’s assets and resources for biotechnology companies at BIO International 2017, which was June 19-22 in San Diego, California. 

Prior to the BIO event, Choose New Jersey President and Chief Executive Officer Michele Brown in June wrote:

When Hurel Corporation outgrew its incubator space at the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick, New Jersey in 2016, it marked an important milestone for the biotechnology company. Continue reading

EVENT: Save the Date! HINJ to Host 2017 Life Sciences Celebration on October 12 in Trenton

New Brunswick, NJ, July 31, 2017 ― Please mark your calendar to join the HealthCare Institute of New Jersey (HINJ) in honoring meritorious leadership in and contributions to New Jersey’s life sciences community at HINJ’s Life Sciences Celebration 2017, which will be held Thursday, October 12 from 8:00 to 10:00 a.m. at the Historic Trenton Masonic Temple. 100 Barrack Street, Trenton.

HINJ’s 2017 honorees are: Continue reading

PhRMA Publishes 2017 Biopharmaceutical Industry Resources; Member Companies Spent $65.5 Billion on R&D in 2016

PhRMA’s 2017 “Chart Pack”

Washington, DC, July 28, 2017 — Did you know that Pharmaceutical Research and Manufacturers of America (PhRMA) member companies invested $65.5 billion in research and development (R&D) in 2016?

Or that combined spending on brand medicines, generics and the supply chain account for 14 percent of total national health spending, with brands accounting for just half of this (7 percent)?

Or that the United States accounts for two thirds of the world’s venture capital investments in high-growth biopharmaceutical startups?

These are but a few of the facts that can be found in PhRMA’s 2017 Biopharmaceutical Research Industry Profile and the 152-page industry chart pack, Biopharmaceuticals in Perspective, which were released July 20.
Continue reading

FDA Commissioner Delays Layoff Notices and Reassures Staff Congress Will Reauthorize User Fees

FDA Commissioner Scott Gottlieb, M.D.

Washington, DC, July 27, 2017 — Michael Mezher reports on Endpoints News that, in a July 24 email to agency staff, FDA commissioner Scott Gottlieb, M.D., said he will delay issuing layoff notices until after September 30, which is when the agency’s current user fee agreements expire.

Previously, the FDA indicated it could issue layoff notices to thousands of staffers funded by user fees should Congress not act by August 1.

In the email, Gottlieb said he is optimistic the Senate will take up the matter soon and the agency can “reasonably expect” reauthorization to occur before the September 30 deadline. Continue reading

Rutgers Cancer Institute of New Jersey Investigators Receive $450K in Fellowship Grants

New Brunswick, NJ, July 27, 2017 — Rutgers Cancer Institute of New Jersey investigators have received $450,000 in funding to support research projects in immunotherapy and basic science research that could impact pancreatic, breast and other cancers.

The Pre- and Post-Doctoral Fellowship Grants were awarded by the New Jersey Commission on Cancer Research (NJCCR).

Eileen White, Ph.D., Rutgers Cancer Institute Deputy Director, Chief Scientific Officer and Associate Director for Basic Science, said, “As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute is dedicated to treatment, prevention, education and research.” Continue reading

Patients and Families Make Emotional Plea at Senate Hearing for Diabetes Research Funding

Washington, DC, July 27, 2017 — Summer Park reports on Roll Call that families and advocates delivered an emotional plea for more diabetes research funding before Congress on July 26.

People with type 1 diabetes, including over 160 children, were on hand for a hearing before the Senate Special Committee on Aging.

Those testifying urged lawmakers to extend the Special Diabetes Program, which funds research into type 1 diabetes.  The program will run out of funds this September if lawmakers don’t act. Continue reading

NJIT Assistant Professor Alice Lee Focuses on ‘A Heart Attack in a Petri Dish’

Newark, NJ, July 25, 2017 — In petri dishes in her campus laboratory at New Jersey institute of Technology (NJIT), Assistant Professor Alice Lee is developing colonies of cardiac cells, formed into chambers, that pump and contract like a human heart.

Derived from stem cells, these primitive organs will help her achieve a research milestone:  to observe in microscopic, real-time detail how the heart repairs itself after injury.

Lee must first induce an “attack” by damaging the tiny proto-hearts with a frozen rod, thus mobilizing sequential, cell-based repair crews that clear the injury site of debris, and then in a second phase, recruit materials and tools from the neighboring tissue to mend the damage. Continue reading